Log In
Print this Print this

INO-8000, VGX-6150

  Manage Alerts
Collapse Summary General Information
Company Inovio Pharmaceuticals Inc.
DescriptionSynCon DNA vaccine covering HCV genotype 1
Molecular Target HCV NS3/4A protease complex ; HCV NS4B transmembrane protein
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: DNA vaccine
Latest Stage of DevelopmentPhase I
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat HCV genotypes 1a and 1b infection
Regulatory Designation


GeneOne Life Science Inc.

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today